These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32344435)

  • 1. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding.
    Daoussis D; Kraniotis P; Filippopoulou A; Argiriadi R; Theodoraki S; Makatsoris T; Koutras A; Kehagias I; Papachristou DJ; Solomou A; Kalofonos H; Liossis SN
    Rheumatology (Oxford); 2020 May; 59(5):1041-1050. PubMed ID: 32344435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.
    Benfaremo D; Manfredi L; Luchetti MM; Gabrielli A
    Curr Drug Saf; 2018; 13(3):150-164. PubMed ID: 29745339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
    Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
    Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
    Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
    Subedi A; Williams SG; Yao L; Maharjan S; Strauss J; Sharon E; Thomas A; Apolo AB; Gourh P; Hasni SA; Gulley JL; Kaplan MJ; Katz JD; Gupta S
    JAMA Netw Open; 2020 Feb; 3(2):e200032. PubMed ID: 32101306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M; Truchetet ME; Schaeverbeke T
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
    Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
    Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study.
    Daoussis D; Melissaropoulos K; Dimitroulas T; Andreadis H; Christopoulou A; Douganiotis G; Makatsoris T; Koutras A; Georgiou P; Kalofonos H
    Mediterr J Rheumatol; 2020 Jun; 31(2):239-241. PubMed ID: 32676566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
    Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
    Braaten TJ; Brahmer JR; Forde PM; Le D; Lipson EJ; Naidoo J; Schollenberger M; Zheng L; Bingham CO; Shah AA; Cappelli LC
    Ann Rheum Dis; 2020 Mar; 79(3):332-338. PubMed ID: 31540935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
    Lee KA; Kim HR; Yoon SY
    Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
    Steven NM; Fisher BA
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.
    Roberts J; Ennis D; Hudson M; Ye C; Saltman A; Himmel M; Rottapel R; Pope J; Hoa S; Tisseverasinghe A; Fifi-Mah A; Maltez N; Jamal S
    Autoimmun Rev; 2020 Aug; 19(8):102595. PubMed ID: 32535092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
    Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
    Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.